Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open-label, Randomized Clinical Trial of Recombinant Human Endostatin (Endo) Combined With Chemotherapy Compared With Chemotherapy for Adjuvant Treatment of Esophageal Cancer

NCT03649945 is registered in ClinicalTrials.gov with First Affiliated Hospital of Guangxi Medical University as lead sponsor.

NCT NCT03649945
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03649945 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open-label, Randomized Clinical Trial of Recombinant Human Endostatin (Endo) Combined With Chemotherapy Compared With Chemotherapy for Adjuvant Treatment of Esophageal Cancer
Lead sponsor
First Affiliated Hospital of Guangxi Medical University
Phase
Phase 2
Overall status
Unknown status
Start date
November 30, 2018
Completion date
May 31, 2021
Enrollment
186 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

esophageal cancer